5/24/2022 7:30:59 AM
Merck: European Commission Approves KEYTRUDA Plus Chemotherapy In Breast Cancer
4/28/2022 6:37:18 AM
Merck Q1 GAAP EPS From Cont Opns $1.70; Non-GAAP EPS $2.14
4/18/2022 7:01:51 AM
Merck: Health Canada Approves KEYTRUDA For Triple-negative Breast Cancer In Combination With Chemotherapy
4/14/2022 7:57:45 AM
Merck Says FDA Grants Breakthrough Therapy Designation For V116 Vaccine
4/11/2022 7:50:18 AM
Merck: Health Canada Approves GARDASIL®9 For Prevention Of Oropharyngeal And Other Head And Neck Cancers
4/1/2022 7:10:38 AM
Merck And Ridgeback To Present Data Showing COVID Antiviral LAGEVRIO Ends Infectious Of SARS-CoV-2 Than Placebo
4/1/2022 7:08:11 AM
Merck Says FDA Extends PDUFA Date Of SBLA For VAXNEUVANCE To July 1
3/15/2022 7:23:16 AM
Merck To Stop Phase 3 KEYLYNK-010 Trial Investigating KEYTRUDA In Combination With LYNPARZA